EN DE
Watch Emyria Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Emyria Ltd (EMD) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Emyria Ltd stock A$0.02, price A$0.04, that is 35.3% below the price, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000073645

EL Emyria Ltd logo Thin data Nov 4, 2026

Emyria Ltd

EMD · AU
Very expensive, weak quality

Our calculation puts a fair price 35% below what the stock costs today.

Mixed Growth (revenue 5y +14.4 %/yr in AUD)
Fair value A$0.0233 · Strongly overvalued
Quality 32/100
Loss-making · -150.8% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 6/100 · thin data
Thin data
⚠ Dilution
Watch Emyria Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.4950 A$0.0230 Fair Value A$0.0233 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range A$0.0230 – A$0.4950 · the A$0.0360 price screens above the A$0.0233 fair value. As of Nov 4, 2026.

Follow Emyria in your weekly email

Every Wednesday you see whether Emyria is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments.

Show moreShow less

It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name.

It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020.

Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Stock analysis

Emyria Ltd (EMD) currently trades at A$0.0360, while our model-based Fair Value estimate is A$0.0233, 35% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Emyria Ltd reported revenue of A$3.9M in FY2026 versus A$1.8M in FY2022, a compound +20.8%/yr. Reported net income was −A$6.1M in FY2026.

Key figures

Market cap A$29.0M (≈ $20.0M) Micro · P/S ratio 7.76 · EPS (TTM) A$−0.0100 · Return on equity −86.4% · Return on assets (EBIT) −79.1% (5-year average) · Operating margin −123% · Revenue (TTM) A$4.1M · Revenue growth (YoY) +239%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 51% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −35%, EMD screens richer than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) n/a A$0.0100 A$0.0100 50
All 1 models by family
Asset-Based
NCAV (Graham) n/a A$0.0100 A$0.0100 50

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 64
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+178.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+66.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−289.0% (2021) → −161.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

EMD screens overvalued: fair value 35% below the price. Compare with Veeva Systems Inc →

Compare Emyria Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −35.3% · Below median
Profitability
Return on assets −53.2% · Bottom 25%
Net margin (12 months) −150.8% · Bottom 25%
Operating margin (12 months) −122.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 239.3% · Top 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 3.28× · Pricier than median
P/S (12 months) 7.16× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)100 · sector 46
PAST (return on equity)0 · sector 10
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $303.73 $334.10 +10% vs EMD
HealthEquity, Inc HQY $103.63 $113.99 +10% vs EMD
Doximity, Inc DOCS $32.51 $35.76 +10% vs EMD
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,823 +10% vs EMD
Waystar Holding WAY $28.35 $29.10 +3% vs EMD
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs EMD
Pro Medicus Limited PME A$205.49 A$85.12 −59% vs EMD
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs EMD
XtalPi Holdings 2228 HK$6.13 HK$1.53 −75% vs EMD
Privia Health Group PRVA $24.42 $5.52 −77% vs EMD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Emyria Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Emyria Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EMD

Frequently asked questions

Is Emyria Ltd (EMD) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.0233 versus a price of A$0.0360, about 35% lower (overvalued).
What is the fair value of EMD?
Our model-based fair value for Emyria Ltd is A$0.0233 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.0360.
What is the quality score of EMD?
Emyria Ltd has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Emyria Ltd (EMD)?
Our model-based price target is the fair value of A$0.0233 (as of Nov 4, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Emyria Ltd stock forecast for 2026?
Our models put fair value at A$0.0233, about 35% lower versus a price of A$0.0360 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Emyria Ltd (EMD)?
Emyria Ltd reported trailing-twelve-month revenue of about A$4.1M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Emyria Ltd (EMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emyria Ltd it is A$0.0233 per share (as of Nov 4, 2026), against a price of A$0.0360. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Emyria Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, EMD trades above its calculated fair value: price A$0.0360, fair value A$0.0233, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EMD?
No. The price is what the market pays today (A$0.0360); the fair value is what the company's own numbers justify (A$0.0233). For Emyria Ltd the two are A$0.0127 per share apart. That gap is exactly why we show both numbers side by side.
How much is Emyria Ltd worth?
The market values Emyria Ltd at about A$29.0M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0360; our models calculate a fair value of A$0.0233 per share.
How solid is the balance sheet of Emyria Ltd (EMD)?
Balance-sheet figures for Emyria Ltd (as of Nov 4, 2026): return on equity −86.4%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is EMD from its 52-week high?
Emyria Ltd trades at A$0.0360, about 51% below its 52-week high of A$0.0740 and at the low of A$0.0360 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0233 is for.
Which stocks are comparable to Emyria Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Emyria Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0360, calculated fair value A$0.0233 (−35%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EMD calculated?
We run Emyria Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.0233 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Emyria Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Emyria Ltd (EMD)?
The closing price on Nov 9, 2026 was A$0.0360. Our model-based fair value is A$0.0233, about 35% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Emyria Ltd right now?
Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Emyria Ltd

How large is the market capitalisation of Emyria Ltd (EMD)?
The market capitalisation of Emyria Ltd is A$29.0M (≈ $20.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Emyria Ltd (EMD)?
The price-to-sales ratio of Emyria Ltd is 7.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Emyria Ltd (EMD)?
Earnings per share at Emyria Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Emyria Ltd (EMD)?
The return on equity (ROE) of Emyria Ltd is −86.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Emyria Ltd (EMD)?
On an EBIT basis the return on assets of Emyria Ltd is −79.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Emyria Ltd (EMD)?
The operating margin of Emyria Ltd is −123% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Emyria Ltd (EMD)?
Revenue at Emyria Ltd is growing +239% versus a year earlier (3y avg +34.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Emyria Ltd (EMD) generate?
The free cash flow of Emyria Ltd is −A$4.9M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Emyria Ltd (EMD) hold?
Emyria Ltd holds more cash than debt, A$6.5M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Emyria Ltd in the live analysis

One click puts Emyria Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.